probucol has been researched along with Diabetes Mellitus, Type 2 in 35 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our aim was to assess the effects of the antioxidant succinobucol (AGI-1067) on cardiovascular outcomes in patients with recent acute coronary syndromes already managed with conventional treatments." | 9.13 | Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. ( Choi, J; Cooper, J; Klug, E; L'Allier, PL; Lewis, EF; McMurray, JJ; Pfeffer, MA; Schumi, J; Scott, R; Small, R; Tardif, JC, 2008) |
| "To clarify whether probucol and statins suppress oxidative stress in diabetic patients, we studied the effects of probucol and the statin atorvastatin on urinary 8-hydroxy-2'deoxyguanosine (8-OHdG) levels in diabetics with hypercholesterolemia." | 9.12 | Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. ( Ebisuno, M; Endo, K; Koide, N; Miyashita, Y; Ohira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M, 2006) |
| "Probucol (PB) is a lipophilic drug with potential applications in type 2 diabetes (T2D)." | 5.43 | Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line. ( Al-Salami, H; Arfuso, F; Mooranian, A; Negrulj, R, 2016) |
| " The 24-h proteinuria levels were significantly reduced in the probucol + telmisartan compared with telmisartan group." | 5.22 | Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study. ( Cai, G; Chen, X; Guan, X; Li, J; Li, W; Liu, M; Liu, W; Liu, Y; Lun, L; Wang, Y; Wu, H; Yao, H; Yin, S; Zhang, J; Zheng, Y; Zhou, C; Zhu, H; Zhuang, X, 2016) |
| "To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers." | 5.22 | Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial. ( Baik, SH; Cha, BS; Choi, SH; Chung, CH; Han, KA; Hwang, YC; Jin, SM; Ko, SH; Lee, HW; Lee, IK; Lee, MK; Nam, MS; Park, IeB; Park, TS; Rhee, EJ; Sohn, TS; Yu, JM, 2016) |
| " Our aim was to assess the effects of the antioxidant succinobucol (AGI-1067) on cardiovascular outcomes in patients with recent acute coronary syndromes already managed with conventional treatments." | 5.13 | Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. ( Choi, J; Cooper, J; Klug, E; L'Allier, PL; Lewis, EF; McMurray, JJ; Pfeffer, MA; Schumi, J; Scott, R; Small, R; Tardif, JC, 2008) |
| "To clarify whether probucol and statins suppress oxidative stress in diabetic patients, we studied the effects of probucol and the statin atorvastatin on urinary 8-hydroxy-2'deoxyguanosine (8-OHdG) levels in diabetics with hypercholesterolemia." | 5.12 | Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. ( Ebisuno, M; Endo, K; Koide, N; Miyashita, Y; Ohira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M, 2006) |
| "Probucol is a diphenolic compound with anti-oxidant and anti-inflammatory properties that reduces atherosclerosis and restenosis." | 4.84 | Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds. ( Hime, N; Stocker, R; Tanous, D, 2008) |
| " Based on previous studies demonstrating the important antioxidant and anti-hyperlipidemic effect of morpholine and 1,4-benzo(x/thi)azine derivatives (A-E), we hereby present the design, synthesis and pharmacological evaluation of novel dual-acting molecules as a therapeutic approach for atherosclerosis." | 3.85 | Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity. ( Katselou, MG; Kourounakis, AP; Matralis, AN, 2017) |
| " A striking exception is probucol, which retards atherosclerosis in carotid arteries and restenosis of coronary arteries after angioplasty." | 3.73 | Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. ( Adams, MR; Beck, K; Choy, K; Croft, KD; Kathir, K; Lau, AK; Li, C; Mori, TA; Stocker, R; Tanous, D; Witting, PK; Wu, BJ, 2006) |
| "Probucol has antioxidant as well as cholesterol-lowering effects." | 2.78 | Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Murano, T; Nagayama, D; Nagumo, A; Ohira, M; Oyama, T; Saiki, A; Sakuma, K; Sasaki, H; Shirai, K; Suzuki, Y; Tatsuno, I; Yamaguchi, T; Yamamura, S, 2013) |
| "Probucol has antioxidant and cholesterol-lowering effects." | 2.72 | Probucol delays progression of diabetic nephropathy. ( Endo, K; Ito, Y; Koide, N; Miyashita, Y; Ohira, M; Otsuka, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M, 2006) |
| "Probucol (PB) is a lipophilic drug with potential applications in type 2 diabetes (T2D)." | 1.43 | Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line. ( Al-Salami, H; Arfuso, F; Mooranian, A; Negrulj, R, 2016) |
| "Probucol treatment normalized CET in all subjects and significantly lowered plasma cholesterol (pre-Rx: 197±4." | 1.43 | Probucol normalizes cholesteryl ester transfer in type 2 diabetes. ( Bagdade, JD; Lane, JT; Subbaiah, PV, 2016) |
| "Probucol (PB) is an antihyperlipidemic and antioxidant drug with the potential to show benefits in T2D." | 1.40 | Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. ( Al-Salami, H; Al-Sallami, HS; Arfuso, F; Chen-Tan, N; Fakhoury, M; Fang, Z; Golocorbin-Kon, S; Matthews, V; Mikov, M; Mooranian, A; Mukkur, TK; Negrulj, R; Watts, GF, 2014) |
| "In patients with type II diabetes mellitus combination therapy with antioxidant probucol decreased the severity of oxidative stress and stabilized carbohydrate metabolism without increasing the dose of hypoglycemic preparations." | 1.32 | Interrelation between compensation of carbohydrate metabolism and severity of manifestations of oxidative stress in type II diabetes mellitus. ( Antonova, KV; Balabolkin, MI; Belenkov, YN; Konovalova, GG; Lankin, VZ; Lisina, MO; Nedosugova, LV; Tikhaze, AK, 2003) |
| " We therefore evaluated in 12 non-insulin-dependent diabetes mellitus subjects the effects of supplementation with alpha-tocopherol (1600 IU/d) and probucol (1 g/d) alone and in combination with an MUFA-enriched diet on LDL and LDL subfraction susceptibility to oxidation and monocyte release of superoxide anion." | 1.29 | Effect of antioxidants alone and in combination with monounsaturated fatty acid-enriched diets on lipoprotein oxidation. ( Barnett, J; Grasse, B; Reaven, P, 1996) |
| "Before treatment, the NIDDM group had a somewhat higher plasma triglyceride level (154 +/- 58." | 1.28 | Lipoprotein composition and HDL particle size distribution in women with non-insulin-dependent diabetes mellitus and the effects of probucol treatment. ( Bagdade, JD; Lane, JT; Otto, ME; Subbaiah, PV, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.86) | 18.7374 |
| 1990's | 7 (20.00) | 18.2507 |
| 2000's | 12 (34.29) | 29.6817 |
| 2010's | 13 (37.14) | 24.3611 |
| 2020's | 2 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Ladopoulou, E | 1 |
| Matralis, AN | 2 |
| Kourounakis, AP | 2 |
| Katselou, MG | 1 |
| Guttapadu, R | 1 |
| Korla, K | 1 |
| Uk, S | 1 |
| Annam, V | 1 |
| Ashok, P | 1 |
| Chandra, N | 1 |
| Mei, X | 1 |
| Zeng, J | 1 |
| Liu, DF | 1 |
| Zhao, Y | 1 |
| Yang, HL | 1 |
| Li, Y | 1 |
| Qiu, P | 1 |
| Tang, MW | 1 |
| Mooranian, A | 5 |
| Zamani, N | 1 |
| Takechi, R | 1 |
| Luna, G | 1 |
| Mikov, M | 4 |
| Goločorbin-Kon, S | 4 |
| Elnashar, M | 1 |
| Arfuso, F | 5 |
| Al-Salami, H | 5 |
| Zhou, G | 1 |
| Wang, Y | 2 |
| He, P | 1 |
| Li, D | 1 |
| Zhang, Q | 1 |
| Liu, T | 1 |
| Ng, CY | 1 |
| Li, G | 1 |
| Negrulj, R | 4 |
| Al-Sallami, HS | 2 |
| Fang, Z | 2 |
| Fakhoury, M | 2 |
| Watts, GF | 2 |
| Matthews, V | 2 |
| Lambros, A | 1 |
| Chen-Tan, N | 1 |
| Mukkur, TK | 1 |
| Zhu, H | 1 |
| Chen, X | 1 |
| Cai, G | 1 |
| Zheng, Y | 1 |
| Liu, M | 1 |
| Liu, W | 1 |
| Yao, H | 1 |
| Li, W | 1 |
| Wu, H | 1 |
| Lun, L | 1 |
| Zhang, J | 1 |
| Guan, X | 1 |
| Yin, S | 1 |
| Zhuang, X | 1 |
| Li, J | 1 |
| Liu, Y | 1 |
| Zhou, C | 1 |
| Bagdade, JD | 2 |
| Lane, JT | 2 |
| Subbaiah, PV | 2 |
| Jin, SM | 1 |
| Han, KA | 1 |
| Yu, JM | 1 |
| Sohn, TS | 1 |
| Choi, SH | 1 |
| Chung, CH | 1 |
| Park, IeB | 1 |
| Rhee, EJ | 1 |
| Baik, SH | 1 |
| Park, TS | 1 |
| Lee, IK | 1 |
| Ko, SH | 1 |
| Hwang, YC | 1 |
| Cha, BS | 1 |
| Lee, HW | 1 |
| Nam, MS | 1 |
| Lee, MK | 1 |
| Endo, K | 3 |
| Saiki, A | 3 |
| Yamaguchi, T | 1 |
| Sakuma, K | 1 |
| Sasaki, H | 3 |
| Ban, N | 1 |
| Kawana, H | 1 |
| Nagayama, D | 1 |
| Nagumo, A | 1 |
| Ohira, M | 3 |
| Oyama, T | 3 |
| Murano, T | 1 |
| Miyashita, Y | 3 |
| Yamamura, S | 1 |
| Suzuki, Y | 1 |
| Shirai, K | 3 |
| Tatsuno, I | 1 |
| Nedosugova, LV | 1 |
| Lankin, VZ | 1 |
| Balabolkin, MI | 1 |
| Konovalova, GG | 1 |
| Lisina, MO | 1 |
| Antonova, KV | 1 |
| Tikhaze, AK | 1 |
| Belenkov, YN | 1 |
| Nomura, S | 1 |
| Takahashi, N | 1 |
| Inami, N | 1 |
| Kajiura, T | 1 |
| Yamada, K | 2 |
| Nakamori, H | 1 |
| Tsuda, N | 1 |
| Koide, N | 2 |
| Otsuka, M | 1 |
| Takeyoshi, M | 2 |
| Ito, Y | 1 |
| Ebisuno, M | 1 |
| Delaigle, AM | 1 |
| Senou, M | 1 |
| Guiot, Y | 1 |
| Many, MC | 1 |
| Brichard, SM | 1 |
| Wu, BJ | 1 |
| Kathir, K | 1 |
| Witting, PK | 1 |
| Beck, K | 1 |
| Choy, K | 1 |
| Li, C | 1 |
| Croft, KD | 1 |
| Mori, TA | 1 |
| Tanous, D | 2 |
| Adams, MR | 1 |
| Lau, AK | 1 |
| Stocker, R | 2 |
| Hime, N | 1 |
| Tardif, JC | 1 |
| McMurray, JJ | 1 |
| Klug, E | 1 |
| Small, R | 1 |
| Schumi, J | 1 |
| Choi, J | 1 |
| Cooper, J | 1 |
| Scott, R | 1 |
| Lewis, EF | 1 |
| L'Allier, PL | 1 |
| Pfeffer, MA | 1 |
| Ishida, K | 1 |
| Shi, K | 1 |
| Mizuno, A | 1 |
| Sano, T | 1 |
| Shima, K | 1 |
| Ikeda, T | 1 |
| Reaven, P | 1 |
| Grasse, B | 1 |
| Barnett, J | 1 |
| Takahara, N | 1 |
| Kashiwagi, A | 2 |
| Nishio, Y | 2 |
| Harada, N | 2 |
| Kojima, H | 1 |
| Maegawa, H | 1 |
| Hidaka, H | 1 |
| Kikkawa, R | 2 |
| Crawford, RS | 1 |
| Mudaliar, SR | 1 |
| Henry, RR | 1 |
| Chait, A | 1 |
| Anikin, VV | 1 |
| Savin, VV | 1 |
| Lupanov, VP | 1 |
| Razygraev, RA | 1 |
| Nishimura, M | 1 |
| Sasaki, T | 1 |
| Ohishi, A | 1 |
| Oishi, M | 1 |
| Kono, S | 1 |
| Totani, Y | 1 |
| Kato, Y | 1 |
| Noto, Y | 1 |
| Misaki, S | 1 |
| Higashi, K | 1 |
| Shimada, F | 1 |
| Wakasugi, H | 1 |
| Inoue, K | 1 |
| Hoshiyama, Y | 1 |
| Russell, JC | 1 |
| Gorogawa, Si | 1 |
| Kajimoto, Y | 1 |
| Umayahara, Y | 1 |
| Kaneto, H | 1 |
| Watada, H | 1 |
| Kuroda, A | 1 |
| Kawamori, D | 1 |
| Yasuda, T | 1 |
| Matsuhisa, M | 1 |
| Yamasaki, Y | 1 |
| Hori, M | 1 |
| Otto, ME | 1 |
| Fonteles, MC | 1 |
| Costa e Forti, A | 1 |
| de Freitas, MT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Multicenter, Randomized, Double Blind, Double-dummy, 16-week, Placebo Controlled Study to Evaluate the Efficacy and Safety of Probucol in Patients With Nephropathy Due to Type 2 Diabetes.[NCT01726816] | Phase 2 | 126 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| "Reduction of Vascular Inflammation and Coronary Atherosclerosis With AGI-1067, a V-Protectant, Reduces Cardiovascular Events in Patients With Coronary Artery Disease"[NCT00066898] | Phase 3 | 6,000 participants | Interventional | 2003-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for probucol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Atr | 2014 |
Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds.
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Diabetes Mellitus, Type 2; Humans; Hypoglyc | 2008 |
Type 2 diabetes: pharmacological intervention in an animal model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arteriosclerosis; Calcium Channel Blockers; Diabe | 2001 |
11 trials available for probucol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: A randomized double-blind placebo-controlled multicenter clinical study.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Benzimidazoles; Benzoates; Blood Glucose; Chol | 2016 |
Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2016 |
Probucol suppresses initiation of chronic hemodialysis therapy and renal dysfunction-related death in diabetic nephropathy patients: Sakura study.
Topics: Aged; Albuminuria; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creati | 2013 |
Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.
Topics: Aged; Analysis of Variance; Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Sele | 2004 |
Probucol delays progression of diabetic nephropathy.
Topics: Aged; Albuminuria; Anticholesteremic Agents; Blood Pressure; Cholesterol; Cholesterol, HDL; Creatini | 2006 |
Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Biomarkers | 2006 |
Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type | 2008 |
Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients.
Topics: Anticholesteremic Agents; Apolipoproteins B; Blood Glucose; Body Mass Index; Cholesterol; Cholestero | 1999 |
[Effect of probucol on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II].
Topics: Aged; Angina Pectoris; Anticholesteremic Agents; Biomarkers; Blood Glucose; Body Mass Index; Cardiac | 2000 |
Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy.
Topics: Acetylglucosaminidase; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antioxida | 2001 |
[Probucol in patients with diabetes mellitus type II with hypercholesterolemia].
Topics: Cholesterol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hyper | 1987 |
21 other studies available for probucol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mel | 2013 |
Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity.
Topics: Animals; Atherosclerosis; Cyclooxygenase 1; Cyclooxygenase 2; Diabetes Mellitus, Type 2; Disease Mod | 2017 |
Identification of Probucol as a candidate for combination therapy with Metformin for Type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Gene Expression Profiling; Metformin; Oxidative Stress; Probucol | 2023 |
Abnormalities of the PRMT1-ADMA-DDAH1 metabolism axis and probucol treatment in diabetic patients and diabetic rats.
Topics: Amidohydrolases; Animals; Arginine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Huma | 2021 |
An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques.
Topics: Administration, Oral; Animals; Capsules; Cardiotoxicity; Diabetes Mellitus, Experimental; Diabetes M | 2019 |
Probucol inhibited Nox2 expression and attenuated podocyte injury in type 2 diabetic nephropathy of db/db mice.
Topics: Albuminuria; Animals; Antioxidants; Collagen Type IV; Diabetes Mellitus, Type 2; Disease Models, Ani | 2013 |
Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes.
Topics: Administration, Oral; Anticholesteremic Agents; Body Fluids; Capsules; Delayed-Action Preparations; | 2015 |
Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol.
Topics: Administration, Oral; Alginates; Diabetes Mellitus, Type 2; Drug Compounding; Drug Delivery Systems; | 2014 |
Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study.
Topics: Administration, Oral; Alginates; Bile Acids and Salts; Calorimetry, Differential Scanning; Capsules; | 2015 |
Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line.
Topics: Animals; Capsules; Cell Line; Cell Survival; Diabetes Mellitus, Type 2; Drug Delivery Systems; Infla | 2016 |
Probucol normalizes cholesteryl ester transfer in type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Case-Control Studies; Cholesterol Es | 2016 |
Interrelation between compensation of carbohydrate metabolism and severity of manifestations of oxidative stress in type II diabetes mellitus.
Topics: Aged; Antioxidants; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; | 2003 |
Induction of adiponectin in skeletal muscle of type 2 diabetic mice: In vivo and in vitro studies.
Topics: Adiponectin; Animals; Antioxidants; Body Weight; Cells, Cultured; Diabetes Mellitus, Type 2; DNA Pri | 2006 |
Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Coronary Restenosis; Diabetes Mellitus, Type 2; Free Ra | 2006 |
The effect of probucol on the development of non-insulin dependent diabetes mellitus in Otsuka Long Evans Tokushima Fatty (OLETF) rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose Tolerance Test; L | 1994 |
Marked decrease in serum HDL cholesterol levels by combined probucol-pravastatin treatment in hypercholesterolemic NIDDM patients.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Comb | 1993 |
Effect of antioxidants alone and in combination with monounsaturated fatty acid-enriched diets on lipoprotein oxidation.
Topics: Adult; Aged; Antioxidants; Diabetes Mellitus, Type 2; Diet; Drug Interactions; Fatty Acids, Monounsa | 1996 |
Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells.
Topics: Antioxidants; Cells, Cultured; Chemokine CCL2; Deferoxamine; Diabetes Mellitus, Type 2; Endothelium, | 1997 |
Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone.
Topics: Antioxidants; Chromans; Copper; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; | 1999 |
Probucol preserves pancreatic beta-cell function through reduction of oxidative stress in type 2 diabetes.
Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Type 2; Female; Injections, Intraperitoneal | 2002 |
Lipoprotein composition and HDL particle size distribution in women with non-insulin-dependent diabetes mellitus and the effects of probucol treatment.
Topics: Aged; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Humans; Lipoproteins; Middle Aged; Probuc | 1991 |